The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals ...

Novartis experienced a strong bull run in 2024 ... Eight current in-market brands, Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix, each hold multi-billion dollar ...

In 2024, three Swiss companies once again made it into the top 100 most valuable companies in the world, despite Roche, ...

Eight blockbuster drugs are expected to generate over $3bn in peak sales each according to Novartis CEO Vas Narasimhan.

Meanwhile, Novartis has secured European approval for a subcutaneous formulation of the anti-CD20 antibody ofatumumab for relapsing forms of multiple sclerosis (RMS) under the Kesimpta brand name.

Novartis announced the success of its Phase III STEER study for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in treating spinal muscular atrophy (SMA) Type 2 in children and ...